Edwards Lifesciences (NYSE:EW) reported fourth-quarter sales of $1.39 billion, beating the consensus of $1.36 billion. This ...

Executives expect a new label indication and a hoped-for easing of hospital capacity constraints to accelerate sales this ...

Atherosclerosis, a disease characterized by the accumulation of lipids and inflammatory cells in the arterial wall, is a ...

A high burden of heart valve diseases is driving its expansion. India’s transcatheter aortic valve replacement (TAVR) market ...

"Smokers face an elevated risk of developing an array of cardiovascular diseases, and many require advanced interventional ...

Earlie Smith experienced an aortic dissection. Months later, her brother, Larry Smith, also had one. The same doctor helped ...

Reports Q4 revenue $1.39B, consensus $1.36B. Q4 TAVR sales grew 6%; constant currency sales grew 5%; Q4 TMTT sales grew 88% to $105 million ...

Edwards Lifesciences had a higher profit and sales in its fourth quarter as demand for its products held strong. The medical-technology company posted a profit of $385.6 million, or 65 cents a share, ...

Although no medical treatment is yet approved, doxycycline has been shown to greatly reduce aortic aneurysm growth in animal models and has been shown to slow growth in several small clinical trials.

Edwards Lifesciences Corp.’s posted fourth quarter results slightly ahead of expectations, but indicated that the first quarter of 2025 might not be as bright. The company expects growth for both its ...

We recently published a list of the 10 Best Medical Device Stocks To Buy According to Hedge Funds. In this article, we are ...

A 12-year-old girl , who was battling a rare and life-threatening heart condition, was successfully treated with a complex surgical procedure at Kauvery Hospital, Vadapalani.